Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 172

1.

Monoclonal gammopathy of undetermined significance: a new proposal of workup.

Mangiacavalli S, Cocito F, Pochintesta L, Pascutto C, Ferretti V, Varettoni M, Zappasodi P, Pompa A, Landini B, Cazzola M, Corso A.

Eur J Haematol. 2013 Oct;91(4):356-60. doi: 10.1111/ejh.12172. Epub 2013 Aug 17.

PMID:
23859528
2.

Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.

Kyle RA, San-Miguel JF, Mateos MV, Rajkumar SV.

Hematol Oncol Clin North Am. 2014 Oct;28(5):775-90. doi: 10.1016/j.hoc.2014.06.005. Epub 2014 Jul 22. Review.

PMID:
25212882
3.

The predictive power of serum kappa/lambda ratios for discrimination between monoclonal gammopathy of undetermined significance and multiple myeloma.

Bergón E, Miravalles E, Bergón E, Miranda I, Bergón M.

Clin Chem Lab Med. 2005;43(1):32-7. Erratum in: Clin Chem Lab Med. 2005;43(3):349.

PMID:
15653439
4.
5.

[Monoclonal gammopathy of undetermined significance and asymptomatic multiple myelom in the year 2014 ].

Adam Z, Krejčí M, Pour L, Sevčíková E, Křivanová A, Rehák Z, Koukalová R, Cermáková Z, Vaníček J, Sevčíková S.

Vnitr Lek. 2014 Oct;60(10):861-79. Review. Czech.

PMID:
25382009
6.

Role of different hematologic variables in defining the risk of malignant transformation in monoclonal gammopathy.

Baldini L, Guffanti A, Cesana BM, Colombi M, Chiorboli O, Damilano I, Maiolo AT.

Blood. 1996 Feb 1;87(3):912-8.

7.

Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.

Magnano L, Fernández de Larrea C, Elena M, Cibeira MT, Tovar N, Aróstegui JI, Pedrosa F, Rosiñol L, Filella X, Yagüe J, Bladé J.

Clin Lymphoma Myeloma Leuk. 2016 Jun;16(6):e71-7. doi: 10.1016/j.clml.2016.02.034. Epub 2016 Feb 27.

PMID:
27013181
8.

Should bone marrow examination be routinely performed for the diagnosis of monoclonal gammopathy of undetermined significance?

Elis A, Radnay J, Shapiro H, Itzhaky D, Manor Y, Lishner M.

Isr Med Assoc J. 2006 Dec;8(12):840-2.

9.

Appearance of monoclonal plasma cell diseases in whole-body magnetic resonance imaging and correlation with parameters of disease activity.

Kloth JK, Hillengass J, Listl K, Kilk K, Hielscher T, Landgren O, Delorme S, Goldschmidt H, Kauczor HU, Weber MA.

Int J Cancer. 2014 Nov 15;135(10):2380-6. doi: 10.1002/ijc.28877. Epub 2014 Apr 17.

10.

[Benign monoclonal gammopathy].

Shirota T, Kondo M, Uchida H, Ito H.

Nihon Rinsho. 1995 Mar;53(3):720-4. Review. Japanese.

PMID:
7699912
11.

Monoclonal gammopathy of undetermined significance: why identification of these patients and assessment of their skeletons is important.

Berenson JR, Yellin O.

Clin Lymphoma Myeloma. 2009 Aug;9(4):311-5. doi: 10.3816/CLM.2009.n.061.

PMID:
19717382
12.

[Analysis of serum levels of Dickkopf-1 (DKK-1) in monoclonal gammopathy of undetermined significance and multiple myeloma].

Ščudla V, Petrová P, Pika T, Lochman P, Minařík J, Bačovský J, Srovnalík K.

Cas Lek Cesk. 2015;154(4):181-8. Czech.

PMID:
26357861
13.

Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.

van de Donk NW, Mutis T, Poddighe PJ, Lokhorst HM, Zweegman S.

Int J Lab Hematol. 2016 May;38 Suppl 1:110-22. doi: 10.1111/ijlh.12504. Epub 2016 May 9. Review.

PMID:
27161311
14.

Can whole-body low-dose multidetector CT exclude the presence of myeloma bone disease in patients with monoclonal gammopathy of undetermined significance (MGUS)?

Spira D, Weisel K, Brodoefel H, Schulze M, Kaufmann S, Horger M.

Acad Radiol. 2012 Jan;19(1):89-94. doi: 10.1016/j.acra.2011.09.016.

PMID:
22142681
15.

Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.

Kyle RA, Rajkumar SV.

Curr Hematol Malig Rep. 2010 Apr;5(2):62-9. doi: 10.1007/s11899-010-0047-9. Review.

16.

Quantification of bone marrow plasma cell infiltration in multiple myeloma: usefulness of bone marrow aspirate clot with CD138 immunohistochemistry.

Matsue K, Matsue Y, Kumata K, Usui Y, Suehara Y, Fukumoto K, Fujisawa M, Narita K, Takeuchi M.

Hematol Oncol. 2017 Sep;35(3):323-328. doi: 10.1002/hon.2300. Epub 2016 May 3.

PMID:
27140172
17.

A GEIL flow cytometry consensus proposal for quantification of plasma cells: application to differential diagnosis between MGUS and myeloma.

Frébet E, Abraham J, Geneviève F, Lepelley P, Daliphard S, Bardet V, Amsellem S, Guy J, Mullier F, Durrieu F, Venon MD, Leleu X, Jaccard A, Faucher JL, Béné MC, Feuillard J; GEIL Groupe d'Etude Immunologique des Leucémies Study Group.

Cytometry B Clin Cytom. 2011 May;80(3):176-85. doi: 10.1002/cyto.b.20581. Epub 2010 Dec 10.

18.

The diagnostic value of SE MRI and DWI of the spine in patients with monoclonal gammopathy of undetermined significance, smouldering myeloma and multiple myeloma.

Dutoit JC, Vanderkerken MA, Anthonissen J, Dochy F, Verstraete KL.

Eur Radiol. 2014 Nov;24(11):2754-65. doi: 10.1007/s00330-014-3324-5. Epub 2014 Aug 9.

PMID:
25106487
19.

Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management.

Hillengass J, Moehler T, Hundemer M.

Recent Results Cancer Res. 2011;183:113-31. doi: 10.1007/978-3-540-85772-3_6. Review.

PMID:
21509683
20.

Active multiple myeloma suppresses and typically eliminates coexisting MGUS.

Campbell JP, Heaney JLJ, Pandya S, Afzal Z, Kaiser M, Owen R, Child JA, Gregory W, Morgan GJ, Jackson GH, Bunce CM, Drayson MT.

Br J Cancer. 2017 Sep 5;117(6):835-839. doi: 10.1038/bjc.2017.229. Epub 2017 Jul 20.

PMID:
28728165

Supplemental Content

Support Center